Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, September 1998, p. 2206-2214, Vol. 42, No. 9
Department of Medicine, Center for the Health
Sciences, Los Angeles, California
Received 12 December 1997/Returned for modification 2 April
1998/Accepted 18 June 1998
Human neutrophils contain two structurally distinct types of
antimicrobial peptides,
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Activities of LL-37, a Cathelin-Associated
Antimicrobial Peptide of Human Neutrophils
-sheet defensins (HNP-1 to HNP-4) and the
-helical peptide LL-37. We used radial diffusion assays and an
improved National Committee for Clinical Laboratory Standards-type broth microdilution assay to compare the antimicrobial properties of
LL-37, HNP-1, and protegrin (PG-1). Although generally less potent than
PG-1, LL-37 showed considerable activity (MIC, <10 µg/ml) against
Pseudomonas aeruginosa, Salmonella typhimurium, Escherichia coli, Listeria monocytogenes,
Staphylococcus epidermidis, Staphylococcus
aureus, and vancomycin-resistant enterococci, even in media that
contained 100 mM NaCl. Certain organisms (methicillin-resistant S. aureus, Proteus mirabilis, and Candida
albicans) were resistant to LL-37 in media that contained 100 mM
NaCl but were susceptible in low-salt media. Burkholderia
cepacia was resistant to LL-37, PG-1, and HNP-1 in low- or
high-salt media. LL-37 caused outer and inner membrane permeabilization
of E. coli ML-35p. Chromogenic Limulus assays
revealed that LL-37 bound to E. coli O111:B4
lipopolysaccharide (LPS) with a high affinity and that this binding
showed positive cooperativity (Hill coefficient = 2.02). Circular
dichroism spectrometry disclosed that LL-37 underwent conformational
change in the presence of lipid A, transitioning from a random coil to
an
-helical structure. The broad-spectrum antimicrobial properties
of LL-37, its presence in neutrophils, and its inducibility in
keratinocytes all suggest that this peptide and its precursor (hCAP-18)
may protect skin and other tissues from bacterial intrusions and
LPS-induced toxicity. The potent activity of LL-37 against
P. aeruginosa, including mucoid and
antibiotic-resistant strains, suggests that it or related molecules
might have utility as topical bronchopulmonary microbicides in cystic
fibrosis.
*
Corresponding author. Mailing address: Department of
Medicine, Center for the Health Sciences, Box 951690, Los Angeles, CA 90095-1690. Phone: (310) 825-5340. Fax: (310) 206-8766. E-mail: rlehrer{at}med1.medsch.ucla.edu.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |